Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Refining and improving treatment options in CLL
Analyses from COMFORT trials of ruxolitinib for myelofibrosis
AL amyloidosis and a critical, early diagnosis
ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel